Provider review
altRX review
Promises the same price at every dose, on two products it identifies only by receptor.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
We may earn a commission at no extra cost to you. Affiliate partners are listed first on our rankings. How we’re funded.
$89/mo GLP-1 · $149/mo GLP-1 with GIP, flat at every dose
Visit altRXBoth compounded figures are promotional with a deadline, but the pre-discount pair is published rather than implied.
Price as published
altRX
$89/mo GLP-1 · $149/mo GLP-1 with GIP, flat at every dose
FDA warning letter · altRX · June 2026 · addressed to Trinity HealthCare Supply, LLC dba altRx. Details in our review.
- Vs median
- $86/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Same price at every dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
The flat-dose promise here is unusually explicit and unusually prominent — it is in the banner, it is beside the call to action, and it is phrased two different ways so it cannot be missed. Taken at face value it means you can choose your dose on clinical grounds alone, which is a real convenience and, for someone titrating upward, a real saving. For someone deliberately holding a quarter dose it is the structure that costs the most, because the bill does not fall when the drug does. The entry figure is among the lowest here, and both compounded figures are promotional with a stated deadline, shown against struck-through prices that are presumably what they return to. That is a more honest form of discounting than most: the pre-discount number is published rather than implied, so you can budget the second scenario as well as the first. The unresolved part is what is actually being sold. Both compounded products are named for the receptors they act on rather than for the drug in the vial. The pairing of a single-target product with a dual-target one at a higher price is a familiar shape, and a familiar shape is not a label. The branded products on the same page are named precisely and priced more than ten times higher, which makes the contrast between what you can identify and what you can afford the clearest thing on the site.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You expect to titrate upward and want the bill to stay where it started
- You want to know the post-promotion price before the promotion ends — it is published
- You want to compare a compounded entry price against branded products on one page
Look elsewhere if
- You want to know which drug you are buying. Both products are named by receptor only
- You intend to hold a quarter dose. A flat price is the most expensive structure for that
- You are budgeting past the deadline. Both entry figures are promotional
What it actually costs
Price as published
$89/mo GLP-1 · $149/mo GLP-1 with GIP, flat at every dose
- Vs median
- $86/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate
- Market
- $59–$1,300/mo is the full published spread on this site
- Structure
- Same price at every dose
One stated price across doses. A lower dose does not automatically reduce the bill. Compare the complete medication, membership, laboratory and shipping quotes before assuming another plan costs less.
113 of the 548 programs here price a small dose this way. The flat-dose promise is stated twice and prominently, in the banner and beside the call to action, so you can choose a dose on clinical grounds alone. If you are deliberately holding a quarter dose, that is the structure that costs the most, because the bill does not fall when the drug does. Both compounded prices are promotional with a stated deadline, but the pre-discount pair is published too, so the later cost is knowable. Neither compounded product names its drug: they are labeled by receptor, so which molecule you would get is not stated. The branded products on the same page are named precisely and priced more than ten times higher.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not confirmed
- Labs
- Not required
- Pricing
- Flat at every dose
What it does well
- The flat-dose promise is stated twice and prominently rather than buried.
- The pre-discount price is published, so the post-promotion figure is knowable.
- The kit is itemized down to syringes and pads, and branded products are priced too.
Pharmacy, labs and oversight
altRX does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
1 of 4 published openly
What altRX publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere on its own pages.
- Not published
- A price you can read before intakeThe figure appears only after an intake quiz, so it cannot be compared before signing up.
- Not published
- What a higher dose costsOne price at every dose, so the bill is knowable before you titrate.
- Published
- FDA warning letter on fileOne is on file. The disclosure and the FDA's own database are directly below.
- On file
FDA warning letter
The U.S. Food and Drug Administration issued a warning letter to altRX in June 2026. It is addressed to Trinity HealthCare Supply, LLC dba altRx — search that name, not ours, to find it. We are not summarizing what it says — read it at the source. This does not change how altRX is listed here or whether we are paid for a click to it, and we would rather you knew both of those things at once.
How the program works
The flat-dose promise here is unusually explicit and unusually prominent — it is in the banner, it is beside the call to action, and it is phrased two different ways so it cannot be missed. Taken at face value it means a reader can choose their dose on clinical grounds alone, which is a real convenience and, for someone titrating upward, a real saving. For someone deliberately holding a quarter dose it is the structure that costs the most, because the bill does not fall when the drug does. The entry figure is among the lowest here, and both compounded figures are promotional with a stated deadline, shown against struck-through prices that are presumably what they return to. That is a more honest form of discounting than most: the pre-discount number is published rather than implied, so a reader can budget the second scenario as well as the first. The unresolved part is what is actually being sold. Both compounded products are named for the receptors they act on rather than for the drug in the vial. The pairing of a single-target product with a dual-target one at a higher price is a familiar shape, and a familiar shape is not a label. The branded products on the same page are named precisely and priced more than ten times higher, which makes the contrast between what a reader can identify and what they can afford the clearest thing on the site.
The honest cons
Neither compounded product names its molecule — both are labeled by receptor only.
- Both compounded figures are promotional and carry a stated deadline.
- A flat price at every dose means a quarter dose costs what a full dose costs.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
altRX is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.
Also consider
Two more programs that price a small dose the way altRX does. Both are partners: we may earn a commission if you start care through these links.
Partner
Collective
$59/mo sema med + $199/yr membership
Same price at every dose
Partner
MEDGm
$299/mo sema · $399/mo tirz after intake
Same price at every dose
Where this sits
#242 of 548
Ordered with the companies that pay us first, and altRX is not one of them. A disclosed partition, not a score.
Compare all 548 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Low dose vs full dose
- Microdosing tirzepatide
- What a flat price costs at a low dose
- The true annual cost of a plan
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
MadeMed
$239/mo flat
- Vs median
- $64/mo above the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Same price at every dose
- Dispensed
- Compounded by Red Rock · AbsoluteRx
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the MadeMed review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.